Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$11.76 USD
+0.17 (1.47%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $11.74 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
MLYS 11.76 +0.17(1.47%)
Will MLYS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for MLYS
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
Mineralys Therapeutics Inc (MLYS) Q2 2024 Earnings Call Transcript Highlights: Significant ...
Stifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Buy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat Trials
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)